Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 7296 (116th)

MMAPPP Act of 2020

referredUnited States· United States Congress· EN

Introduced

22 June 2020

Last action

22 June 2020 · Introduced

Status

Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Sponsors

Rep. Schakowsky, Janice D. [D-IL-9], Rep. Rooney, Francis [R-FL-19], Rep. Doggett, Lloyd [D-TX-37], Rep. DeLauro, Rosa L. [D-CT-3], Rep. DeFazio, Peter A. [D-OR-4], Rep. Pocan, Mark [D-WI-2], Rep. Jayapal, Pramila [D-WA-7], Rep. Velázquez, Nydia M. [D-NY-7], Rep. Bishop, Sanford D. [D-GA-2], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Hayes, Jahana [D-CT-5], Sen. Welch, Peter [D-VT], Rep. McCollum, Betty [D-MN-4], Rep. Pingree, Chellie [D-ME-1], Rep. Carson, André [D-IN-7], Rep. Raskin, Jamie [D-MD-8], Rep. Cohen, Steve [D-TN-9], Rep. Huffman, Jared [D-CA-2], Rep. Porter, Katie [D-CA-47], Rep. Scanlon, Mary Gay [D-PA-5], Rep. Khanna, Ro [D-CA-17], Michael San Nicolas, Rep. Napolitano, Grace F. [D-CA-32], Rep. Luria, Elaine G. [D-VA-2], Rep. Hastings, Alcee L. [D-FL-20], Rep. Gabbard, Tulsi [D-HI-2], Rep. Chu, Judy [D-CA-28], Rep. DeSaulnier, Mark [D-CA-10], Rep. Lawson, Al, Jr. [D-FL-5], Rep. Rose, Max [D-NY-11], Rep. Grijalva, Raúl M. [D-AZ-7], Rep. Evans, Dwight [D-PA-3], Rep. Price, David E. [D-NC-4], Rep. Titus, Dina [D-NV-1], Rep. Phillips, Dean [D-MN-3]

Subjects

Healthcare

Source updated

10 January 2026

Healthcare

Official sourceDownload fileView documentsShare

Summary

Make Medications Affordable by Preventing Pandemic Price gouging Act of 2020 or the MMAPPP Act of 2020 This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies. With respect to a COVID-19 drug patent developed using certain types of federal support, any license granted by the federal government shall be open and nonexclusive. Similarly, a licensee or assignee for such a patent shall grant open nonexclusive licenses for the patent. An entity that receives a license shall pay reasonable royalties to (1) the patent holder, or (2) the owner of marketing exclusivity rights granted by the Food and Drug Administration (FDA) that were terminated under this bill. The bill requires that such drugs be offered at a fair and reasonable price based on certain considerations, such as access. If the Department of Health and Human Services (HHS) finds that the price of any drug to address a public health emergency is excessive, HHS must void any FDA-granted exclusivity for the drug and grant open and nonexclusive licenses to other manufacturers. Such licenses are subject to reasonable royalty requirements.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 22 June 2020

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  2. 22 June 2020

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 22 June 2020

    Introduced

    Introduced in House

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 22 June 2020

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 22 June 2020

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 22 June 2020

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.